A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Phase 2

Completed

Brief Summary: This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.

Detailed Description: Oregovomab is an investigational drug previously used in clinical trials as an immunotherapeutic treatment of ovarian cancer patients whose tumor cells express the tumor associated antigen, CA125. The active component of oregovomab is the activated murine monoclonal antibody B43.13, an immunoglobulin G1k (IgG1k) subclass immunoglobulin that binds with high affinity (1.16E10/M) to CA125.

CA125 is a surface glycoprotein antigen that is expressed on more than 80% of all non-mucinous epithelial ovarian carcinomas where it occurs at elevated levels in the serum of patients with ovarian cancer. Little is known about its biological function. CA125 is associated with a large molecular weight mucin-like glycoprotein complex of 200-250 kilodaltons (kDa) and its genetic structure has recently been elucidated. There is good evidence to suggest that CA125 is a relevant target antigen for antigen-mediated immunotherapy of ovarian cancer.

The study will compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.

Recruitment & Eligibility

Inclusion Criteria

have newly diagnosed epithelial adenocarcinoma of ovarian, tubal or peritoneal origin and French Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) Stage III/IV disease.
have preoperative CA125 levels > 50 U/mL
have optimal cytoreduction (RT<1)
be anticipated to have first-line chemotherapy infusion within 6 weeks after surgery
be available to complete the protocol for the duration of the study
have adequate Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/µL, equivalent to Common Terminology Criteria (CTCAE v3.0) grade 1. Platelets greater than or equal to 100,000/µL; hemoglobin greater than or equal to 8.0 g/dL
have adequate Renal function: creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), CTCAE v3.0 grade 1
have adequate Hepatic function: bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1). SGOT and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
able to sign informed consent and provide authorization permitting release of personal health information
have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Exclusion Criteria

have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis)
have a known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or cannot tolerate cyclophosphamide
are being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids.
have a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia
have an acquired, hereditary, or congenital immunodeficiency
have uncontrolled diseases other than cancer
have contraindications to the use of pressor agents
have undergone more than one surgical debulking
have hepatic dysfunction, eg, bilirubin more than 1.5 times higher than normal levels, lactate dehydrogenase (LDH), serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) doubled compared to normal or albumin <3.5 g/dL
have severe renal insufficiency with serum creatinine >1.6 mg/dL
have concomitant diseases or treatments that may confound the results of the study, which may preclude the completion of the protocol or may mask adverse reactions
are to be tested with other medications during treatment
are unable to read or understand or unable to sign the necessary written consent before starting treatment

Arm && Interventions

Group	Intervention	Description
carboplatin & paclitaxel & oregovomab	oregovomab	first-line chemotherapy for ovarian cancer plus oregovomab
carboplatin & paclitaxel	Carboplatin	first-line chemotherapy for ovarian cancer
carboplatin & paclitaxel	Paclitaxel	first-line chemotherapy for ovarian cancer
carboplatin & paclitaxel & oregovomab	Carboplatin	first-line chemotherapy for ovarian cancer plus oregovomab
carboplatin & paclitaxel & oregovomab	Paclitaxel	first-line chemotherapy for ovarian cancer plus oregovomab

Primary Outcome Measures

Name	Time	Method
CA125 ELISPOT assay response for cytotoxic T cell antigen specific immunity induction to end of first-line chemotherapy	At Baseline (up to 4 weeks before Cycle 1), at Cycle 5 (approximately 12 weeks after Cycle 1) and termination (approximately 25 weeks after Cycle 1)	Change from baseline CA125 ELISPOT assay after stimulation with oregovomab (MAb-B43.13 against CA125) measured at approximately 12 weeks and 25 weeks after the start of first-line chemotherapy

Secondary Outcome Measures

Name	Time	Method
Immune parameters: HAMA (human anti-mouse antibody) titers and DTH (delayed type hypersensitivity)	Up to three years after treatment in the study	Laboratory test for human anti-mouse antibody (HAMA) present in patients' sera. DTH (delayed type hypersensitivity) is an on-site test conducted by the investigator by injecting a small amount of the Oregovomab product and three other antigens (mumps, tetanus, and Candida) into the skin of the patient and observing the effects.
Clinical response	Up to three years after treatment in the study	Patients will be categorized into one of the following: increasing disease, stable disease, or progression \[measurable disease studies\]
Overall Survival	Up to three years after treatment in the study	The observed length of life from entry into the study to death or the date of last contact
Time to clinical relapse	Up to three years after treatment in the study	The time period from the date of randomization to the date of confirmed relapse as defined by clinical, radiologic, and/or pathologic evaluations.

Locations (2): University of Connecticut Health Center
🇺🇸
Farmington, Connecticut, United States
Northern Indiana Cancer Research Consortium
🇺🇸
South Bend, Indiana, United States